EMERYVILLE, Calif.--(BUSINESS WIRE)--NovaBay Pharmaceuticals, Inc. (AMEX & TSX: NBY, http://www.novabaypharma.com), a clinical stage company developing non-antibiotic anti-infective compounds, for the treatment or prevention of a wide range of bacterial, fungal, and viral infections without inducing resistance, has notified the Toronto Stock Exchange (TSX) of its intent to voluntarily remove its listing of common stock from the TSX in order to consolidate trading on the American Stock Exchange.
